Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
J P Rissing

Abstract

The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose beta-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral beta-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.

References

Jan 1, 1992·The Pediatric Infectious Disease Journal·M A JacksonL C Olson
Jun 1, 1987·The American Journal of Medicine·S L Mader, M Wong
Jan 1, 1974·Scandinavian Journal of Infectious Diseases·S A Hedström
Aug 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·X Sáez-LlorensC Cantón
Feb 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C M RademakerJ Verhoef

❮ Previous
Next ❯

Citations

Apr 2, 2013·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Simon Matthew GrahamJonathan Sandoe
Sep 14, 2002·Current Infectious Disease Reports·Edna Toubes, John Segreti
May 24, 2000·Comprehensive Therapy·D M Bamberger
Sep 20, 2001·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·S IsefukuA H Simpson
Nov 3, 2001·International Journal of Antimicrobial Agents·H von BaumH G Sonntag
Jun 23, 2010·Seminars in Plastic Surgery·Henry S Fraimow
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·William J Jeffcoate, Benjamin A Lipsky
Aug 2, 2002·The Pediatric Infectious Disease Journal·Otto M Ramos
Sep 10, 2010·Journal of Paediatrics and Child Health·Annaleise R Howard-Jones, David Isaacs
Dec 22, 1999·Antimicrobial Agents and Chemotherapy·R N GreenbergR W Pectol
Jul 6, 2000·Drugs·K Kanellakopoulou, E J Giamarellos-Bourboulis
Sep 28, 2013·The Journal of Antimicrobial Chemotherapy·Baek-Nam KimMyoung-Don Oh
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·J J Heckman, E J Vytlacil
Apr 22, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael L LandrumMichael A Forgione
Nov 12, 2009·Infection·S EspositoUNKNOWN Bone Joint Infections Committee for the Italian Society of Infectious Tropical Diseases (SIMIT)
Jan 8, 2013·Expert Opinion on Drug Delivery·Otto S KluinDaniëlle Neut
May 12, 2009·Enfermedades infecciosas y microbiología clínica·Juan-Ignacio Alós
Nov 26, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Se Heang OhJin Ho Lee
Jun 28, 2003·The American Journal of Medicine·Alan D TiceDavid A Shoultz
Jan 31, 2008·Journal of Chemotherapy·E SennevilleY Yazdanpanah
Nov 26, 2003·Clinics in Podiatric Medicine and Surgery·Thomas ZgonisPeter Blume
Aug 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elie F Berbari Infectious Diseases Society of America
Jul 24, 2012·Seminars in Vascular Surgery·Afsoon D Roberts, Gary L Simon
Jun 5, 2003·Clinical Orthopaedics and Related Research·Bridget RutledgeJeff Anglen
Oct 12, 2004·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Louis M HuneaultCyril Désévaux
Nov 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael A NowakMark A Beilke
Mar 23, 2006·The Journal of Antimicrobial Chemotherapy·L MalincarneF Baldelli
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Juan García-Lechuz, Emilio Bouza
Mar 17, 2011·Expert Opinion on Pharmacotherapy·Jaime Esteban, José Cordero-Ampuero
Sep 18, 2001·Equine Veterinary Journal·P H Ramzan, R C Pilsworth
Dec 7, 2002·Journal of Orthopaedic Surgery·Myung-Sang Moon, Jeong-Lim Moon
Sep 10, 2013·The Cochrane Database of Systematic Reviews·Lucieni O Conterno, Marilia D Turchi
Oct 19, 2019·Tissue Engineering and Regenerative Medicine·Sun Woo JungJin Ho Lee
Sep 28, 2001·The Annals of Pharmacotherapy·J A Paladino
Jun 1, 2000·Infectious Disease Clinics of North America·J A O'Donnell, S P Gelone

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.